Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | GLA | P06280 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548634 | 0.86 | KDM4E (0.52) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL6010447 | 0.83 | ALDH1A1 (0.52) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL6009527 | 0.83 | ALDH1A1 (0.59) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL3042946 | 0.81 | KDM4E (0.51) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL2551492 | 0.81 | KDM4E (0.47) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL3038784 | 0.81 | KDM4E (0.55) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL1115932 | 0.80 | ALDH1A1 (0.50) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3634969 | 0.80 | ALDH1A1 (0.68) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL4179195 | 0.80 | ALDH1A1 (0.61) | KDM4EMAPTMEN1RECQLKMT2A | |
| SCHEMBL6009501 | 0.78 | ALDH1A1 (0.62) | KDM4EMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| EP-3860994-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | The University of British Columbia (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020069625-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-09 | — | — | WO | disclosed |
| US-10011578-B2 | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180022722-A1 | Compounds for Stabilizing Ryanodine Receptors from Aberrant Levels of Calcium Release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 2018-01-25 | — | — | US | disclosed |
| US-9725429-B2 | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160207908-A1 | BROAD SPECTRUM ANTIVIRAL AND ANTIPARASITIC AGENTS | NIH-DEITR | 2016-07-21 | — | — | US | disclosed |
| US-20160207908-A1 | BROAD SPECTRUM ANTIVIRAL AND ANTIPARASITIC AGENTS | NIH-DEITR | 2016-07-21 | — | — | US | disclosed |
| US-20160024038-A1 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 2016-01-28 | — | — | US | disclosed |
| US-9102645-B2 | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2014144654-A1 | COMPOUNDS FOR STABILIZING RYANODINE RECEPTORS FROM ABERRANT LEVELS OF CALCIUM RELEASE | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275112-A1 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130028966-A1 | Broad Spectrum Antiviral and Antiparasitic Agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028966-A1 | Broad Spectrum Antiviral and Antiparasitic Agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
| US-8338465-B2 | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2011130419-A2 | BROAD SPECTRUM ANTIVIRAL AND ANTIPARASITIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130419-A2 | BROAD SPECTRUM ANTIVIRAL AND ANTIPARASITIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | CORNELL RESEARCH FOUNDATION, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2008005651-A2 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | DECODE CHEMISTRY, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022722-A1 | Compounds for Stabilizing Ryanodine Receptors from Aberrant Levels of Calcium Release | CHERP, RYR1, RYR2 | KDM4E 2730/4885MAPT 154/4885MEN1 3829/4885 |
| US-20140275112-A1 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release | CHERP, RYR1, RYR2 | KDM4E 2730/4885MAPT 154/4885MEN1 3829/4885 |
| US-20160207908-A1 | BROAD SPECTRUM ANTIVIRAL AND ANTIPARASITIC AGENTS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2367/4885MAPT 2628/4885MEN1 3742/4885 |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | KDM4E 2015/4885MAPT 1816/4885MEN1 297/4885 |
| US-10011578-B2 | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | CHERP, RYR1, RYR2 | KDM4E 2730/4885MAPT 154/4885MEN1 3829/4885 |
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | RARG, SDHA, RARS2 | KDM4E 4138/4885MAPT 3973/4885MEN1 3585/4885 |
| US-20130028966-A1 | Broad Spectrum Antiviral and Antiparasitic Agents | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2367/4885MAPT 2628/4885MEN1 3742/4885 |
| US-20160024038-A1 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release | CHERP, RYR1, RYR2 | KDM4E 2730/4885MAPT 154/4885MEN1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.